NCT07375654CompletedPhase 1
Combined Use of Cyclosporine and Metformin in Treatment of Psoriasis vs Cyclosporine Alone
A Comparative Study on the Efficacy of The Combined Use of Cyclosporine and Metformin in the Treatment of Psoriasis vs Cyclosporine Alone
Source: ClinicalTrials.gov · Last updated 29 Jan 2026
Brief summary (registry, in English)
This study is a comparative clinical study evaluating the efficacy of combined therapy using cyclosporine and metformin versus cyclosporine alone in the treatment of psoriasis. Psoriasis is a chronic inflammatory skin disease that often requires systemic therapy in moderate to severe cases. Cyclosporine is an effective immunosuppressive agent; however, its long-term use is limited by potential adverse effects. Metformin, a commonly used antidiabetic drug, has shown anti-inflammatory and immunomodulatory properties, which may enhance treatment outcomes in psoriasis. This study aims to assess whether adding metformin to cyclosporine improves clinical response compared to cyclosporine monotherapy.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- First submitted
- 7 Jan 2026
- Start date
- 19 Dec 2024
- Primary completion date
- 4 Oct 2025
- Lead sponsor
- Cairo University
- Diseases
- Psoriasis
- NCT number
- NCT07375654
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 32
- From 19 Dec 2024 to the primary completion date, 4 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients receiving systemic treatment relevant to psoriasis within 3 months before enrollment into the study or topical treatment relevant to psoriasis within 1 month before.
Other illness
- Patients with systemic illness ( renal, hepatic and uncontrolled hypertension ).
- Patients with other dermatological conditions.
Other
- Erythrodermic and pustular psoriasis.
- Pregnant and lactating females.
- Patients with high uric acid level .
Who the study is looking for
- Patients ≥ 18 years old
- Patients of both genders
- Patients clinically diagnosed as moderate to severe psoriasis candidate for systemic treatment with Psoriasis Area Severity Index (PASI \>10), Body Surface Area (BSA\>10), Dermatology Life Quality Index (DLQI\>10).(Laura Salgado-Boquete et al., 2021).
- Patients with new active lesions and also patient with chronic lesions (with periods of remission and exacerbation)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cairo University Coordinator of this site? Confirm its status | Cairo | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.